Efficacy Observation of Metadoxine Combined with Tiopronin in the Treatment of Alcoholic Liver Disease
10.6039/j.issn.1001-0408.2017.08.23
- VernacularTitle:美他多辛联合硫普罗宁治疗酒精性肝病的疗效观察
- Author:
Jingang DONG
;
Jinying DONG
- Keywords:
Alcoholic liver disease;
Tiopronin;
Metadoxine;
Therapeutic efficacy
- From:
China Pharmacy
2017;28(8):1091-1094
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical efficacy of metadoxine combined with tiopronin in the treatment of alcoholic liver disease.METHODS:In retrospective study,70 patients with alcoholic liver disease were selected from Shanxi Provincial People's Hospital and Taiyuan Third People's Hospital during Oct.2013-Dec.2015,and then divided into treatment group and control group with 35 cases in each group according to therapy plan.Control group was additionally given Tiopronin enteric-coated tablet 0.2 g,po,tid,based on routine treatment;treatment groups was additionally Metadoxine tablet 1.0 g,po,bid,on the basis of control group.Both groups received treatment for 6 weeks.Serum indicators as ALT,AST,γ-GT,TBIL,TC,TG and A/G and serum hepatic fibrosis indicators as Ⅳ-C,HA and Ln were observed in 2 groups before and after treatment as well as the diameters of MPV and SPV,spleen thickness and clinical efficacy.The occurrence of ADR was recorded.RESULTS:The serum levels of ALT,AST,y-GT,TBIL,TC and TG were decreased significantly in 2 groups,while A/G level was increased significantly;above indicators of treatment group were more significant than those of control group,with statistical significance (P＜0.05).Serum levels of Ⅳ-C,HA,Ln,MPV,SPV and spleen thickness in treatment group were significantly decreased and lower than in control group,with statistical significance (P＜0.05).Total response rate of treatment group (94.29％) was significantly higher than that of control group (62.86％),with statistical significance (P＜0.05).No obvious ADR was found in 2 groups.CONCLUSIONS:Metadoxine combined with tiopronin shows good therapeutic efficacy for alcoholic liver disease with good safety.
